Broad-spectrum Anti-bovine viral diarrhea virus mRNA vaccine and use thereof
By developing trivalent mRNA vaccines, the E2 protein domain I-II fusion protein expressing BVDV1a, BVDV1b and BVDV2, combined with the IgG1 Fc domain, the existing vaccines have solved the insufficient protection and safety of BVDV2, and achieved the multiple BVDVs Efficient immune protection and rapid response capabilities of genotypes.
Patent Information
- Application Number
- PCT/CN2023/127676
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-15
- Filing Date
- 2023-10-30
- Publication Date
- 2024-11-21
AI Technical Summary
The existing BVDV vaccines have protective effects on the BVDV1a and BVDV1b genotypes, but they have weak protection against the BVDV2 genotype and cannot effectively resist strong virulence infection. Inactivated vaccines and recombinant gene vaccines have immune tolerance and safety. Problem, the need for rapid vaccination for sudden large-scale epidemics cannot be dealt with.
Develop a trivalent mRNA vaccine to enhance immunogen by expressing the tandem antigen fusion protein of the E2 protein domain I-II of BVDV1a, BVDV1b and BVDV2 using the mRNA platform to synthesize in vitro, combining the IgG1 Fc domain that aids secretion, and enhances the immunogen. , forming broad-spectrum antibodies.
It has achieved efficient immune protection against a variety of BVDV genotypes, reduced vaccine dose and liposome usage, reduced toxicity, and has the advantages of rapid development and production, which can induce a significant immune response in mice.
Smart Images

Figure CN2023127676_21112024_PF_FP_ABST
Abstract
Description
A broad-spectrum mRNA vaccine against bovine viral diarrhea virus and its application Technical Field
[0001] The present invention relates to the field of biomedicine technology, in particular to the field of animal vaccines, in particular to an mRNA vaccine with broad-spectrum resistance to bovine viral diarrhea virus and applications thereof. Background Art
[0002] Bovine viral diarrhea virus (BVDV) is the main pathogen causing bovine viral diarrhea and is widely found in wild and domestic ruminants. BVDV belongs to the genus Pestivirus and the family Flaviviridae. Clinically, BVDV mainly causes symptoms such as diarrhea, reproductive disorders, immunosuppression, and mucosal erosion and necrosis. The virus is widely present worldwide, causing significant losses to the livestock industry. In particular, BVDV can persist and spread widely in cattle herds, seriously affecting the production capacity of cattle, leading to decreased milk production, decreased milk quality, growth retardation, and stunted development.
[0003] BVDV has two main genotypes: BVDV1 and BVDV2. BVDV1 is the classic strain, encompassing subtypes such as BVDV 1a, BVDV 1b, BVDV 1e, BVDV 1g, and BVDV 1h. BVDV1 primarily causes diarrhea and is clinically detected at a significantly higher rate than BVDV2. BVDV2 can also cause diarrhea, but it is more virulent and can cause acute illness, thrombocytopenia, and hemorrhagic syndrome in adult cattle.
[0004] Currently, the strains isolated in my country are primarily BVDV1a, BVDV1b, and BVDV2 genotypes. Most vaccines currently available target BVDV1a and BVDV1b, but their overall potency is low and their protection is limited. Furthermore, there is no effective vaccine against the BVDV2 genotype, and type 1 offers weak cross-protection against type 2, making it ineffective against infection with highly virulent viruses. BVDV is a single-stranded, positive-strand RNA that encodes four structural proteins (C, E0, E1, and E2) and eight non-structural proteins (Npro, P7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B). The E2 protein is a key structural protein of BVDV, containing the primary antigenic determinant, is highly immunogenic, and can induce the production of neutralizing antibodies, effectively preventing BVDV infection. Studies have found that the E2 protein has low homology between BVDV1 and BVDV2, resulting in a monovalent E2 vaccine that can only protect against BVDV strains of the same type. The E2 protein's extracellular domain is primarily divided into three domains, with domains I-II exposed on the viral surface. Therefore, the development of a multivalent vaccine that can protect against both BVDV types 1 and 2 is crucial for the prevention and control of bovine viral diarrhea.
[0005] A variety of BVDV vaccines have been disclosed in the prior art. Patent document CN115381935A (publication date November 25, 2022) discloses a method for preparing an inactivated BVDV vaccine, comprising the following steps: mixing a BVDV strain virus solution with a hydrogen peroxide solution to a hydrogen peroxide concentration of 1%-3%, inactivating the BVDV strain inactivated virus solution, mixing the inactivated BVDV strain virus solution with Freund's adjuvant, and emulsifying the inactivated BVDV vaccine. Patent document CN110331155B (publication date May 13, 2022) discloses a method for constructing a high-fertility attenuated swine fever marker vaccine carrying the type 2 BVDV-Erns gene. Using molecular cloning and reverse genetics, the Erns gene of the BVDV2-890# strain and the VR1 region of the E2 gene of the epidemic CSFV strain QZ14 were replaced with the corresponding gene fragments of the CSFV-C strain, and seven specific mutation sites were introduced to generate the recombinant virus rC-Marker2. The resulting recombinant virus carries a molecular marker (BVDV2 Erns), VR1 of the epidemic CSFV type 2 strain, and specific mutation sites. However, the main disadvantages of inactivated vaccines include a short duration of immune effect, a relatively long vaccination period requiring multiple doses, and the risk of adverse reactions. Disadvantages of recombinant gene vaccines include safety concerns, the possibility of mutations caused by small amounts of plasmid DNA inserted into chromosomes, and immune tolerance issues. The continuous production of antigenic proteins in the body after gene vaccination may disrupt the body's immune balance and induce immune tolerance.
[0006] Inactivated and recombinant protein vaccines have long production cycles and complex processes, making them unsuitable for the large-scale vaccination required for sudden, large-scale epidemics. mRNA, however, offers a rapid-response vaccine development platform for addressing outbreaks. In recent years, mRNA (messenger RNA) vaccines developed by several companies domestically and internationally have initiated clinical trials, providing preliminary data on their safety and efficacy. mRNA vaccines are synthesized in vitro using linearized plasmid DNA as a template through an enzymatic transcription reaction. This synthesis strategy avoids the safety and complex production processes associated with live cell culture production. The mRNA vaccine platform is safe, effective, has a short production cycle, and features a simple process, making it particularly suitable for addressing outbreaks. It is known in the art that mRNA is rapidly translated, has a rapid onset of action, and inherently activates the immune response. Furthermore, mRNA drugs are simple to produce, easily modified, rapidly synthesized, and inexpensive. More importantly, mRNA drugs are not restricted to dividing cells, pose no risk of integration into the host genome, and are subject to spontaneous degradation in vivo. Therefore, the development of mRNA vaccines offers significant advantages. However, no effective multivalent mRNA vaccine for BVDV prevention and treatment has been identified. There is an urgent need in this field for a fusion protein multivalent antigen BVDV mRNA vaccine that can simultaneously express multiple BVDV genotypes, has strong immunogenicity, and can prevent or treat infections caused by multiple BVDV genotype strains, thereby effectively preventing and controlling bovine viral diarrhea and reducing losses in agriculture and animal husbandry.
[0007] Summary of the Invention
[0008] In order to overcome the defects of the existing BVDV inactivated vaccines, recombinant protein vaccines, recombinant gene vaccines, etc., the present invention provides a tandem antigen fusion protein that simultaneously expresses the E2 protein domains I-II of three BVDV genotypes, BVDV1a, BVDV1b and BVDV2, nucleic acids and mRNA encoding the same, a trivalent BVDV vaccine comprising the mRNA, and related preparation methods and applications. Compared with the strategy of expressing the E2 protein of a single BVDV genotype, the present invention provides a more effective trivalent BVDV mRNA vaccine against multiple genotypes of BVDV strains, which is an antigen selection strategy that is more conducive to industrial application. In addition, the antigen fusion protein of the present invention is fused with the IgG1 Fc domain that helps solubilize and secrete, thereby significantly enhancing the immunogenicity of the E2 protein and increasing the neutralizing antibodies against BVDV produced in the body of the administered subject.
[0009] One aspect of the present invention provides a BVDV antigen fragment, characterized in that it comprises two immunoglobulin-like (Ig-like) domains near the N-terminus of the BVDV E2 protein, namely, BVDV E2 protein domains I-II. Figure 4 shows a schematic diagram of the spatial structure position of BVDV E2 domains I-II, and the referenced BVDV E2 protein structure (PDB: 4ILD), wherein the two immunoglobulin-like (Ig-like) domains correspond to Dom.I and Dom.II in Figure 4. The immunoglobulin-like domain has a self-stabilizing feature, and the spatial structure it forms is not affected by the upstream and downstream sequences; the immunoglobulin-like domain contains a β-sheet structure with a Greek key topological conformation.
[0010] Furthermore, the BVDV antigen fragment is characterized by comprising one or more of BVDV1a E2 protein domains I-II, BVDV1b E2 protein domains I-II, and / or BVDV2 E2 protein domains I-II.
[0011] One aspect of the present invention provides a BVDV antigen fusion fragment, characterized in that it comprises an IgG1 Fc fragment fused with one or more of BVDV1a E2 protein domains I-II, BVDV1b E2 protein domains I-II and / or BVDV2 E2 protein domains I-II.
[0012] Furthermore, the antigen fusion fragment is characterized in that the IgG1 Fc fragment is a bovine IgG1 Fc fragment.
[0013] One aspect of the present invention provides a trivalent BVDV antigen fusion fragment, characterized in that it comprises an IgG1 Fc fragment, BVDV1a E2 protein domains I-II, BVDV1b E2 protein domains I-II, and BVDV2 E2 protein domains I-II.
[0014] Furthermore, the trivalent BVDV antigen fusion fragment is characterized in that the trivalent BVDV antigen fusion fragment comprises, from N-terminus to C-terminus, a bovine IgG1 Fc fragment, BVDV1a E2 protein domains I-II, BVDV1b E2 protein domains I-II, and BVDV2 E2 protein domains I-II.
[0015] Furthermore, the trivalent BVDV antigen fusion fragment is characterized in that the trivalent BVDV antigen fusion fragment also contains a secretion signal peptide.
[0016] One aspect of the present invention provides a BVDV antigen fusion protein, characterized by comprising any one of the following sequences:
[0017] (I) the amino acid sequence shown in SEQ ID NO. 1;
[0018] (II) an amino acid sequence obtained by substituting, deleting or adding one or more amino acid residues of the amino acid sequence shown in SEQ ID NO. 1, and having the same function as the amino acid sequence shown in (I); or
[0019] (III) an amino acid sequence having at least 90% sequence identity with the sequence described in (I) or (II), and having the same function as the amino acid sequence shown in (I).
[0020] One aspect of the present invention provides a recombinant nucleic acid, characterized in that it comprises a nucleic acid encoding the BVDV antigen fragment, or the BVDV antigen fusion fragment, or the trivalent BVDV antigen fusion fragment, or the BVDV antigen fusion protein.
[0021] Furthermore, the recombinant nucleic acid is characterized by comprising any of the following sequences:
[0022] (I) the nucleic acid sequence shown in SEQ ID NO. 2;
[0023] (II) a nucleic acid sequence obtained by replacing, deleting or adding one or more nucleotides of the nucleic acid sequence shown in SEQ ID NO. 2, and having the same function as the nucleic acid sequence shown in (I); or
[0024] (III) A nucleic acid sequence having at least 90% sequence identity with the sequence described in (I) or (II), and having the same function as the nucleic acid sequence shown in (I).
[0025] One aspect of the present invention provides a recombinant mRNA, characterized in that it comprises mRNA encoding the BVDV antigen fragment, or the BVDV antigen fusion fragment, or the trivalent BVDV antigen fusion fragment, or the BVDV antigen fusion protein.
[0026] Furthermore, the recombinant mRNA is characterized in that the mRNA further comprises one or more of a 5'-UTR, a 3'-UTR, a polyA sequence, and an IRES sequence.
[0027] Furthermore, the recombinant mRNA is characterized in that the sequence of the 5'-UTR is shown as SEQ ID NO.3, the sequence of the 3'-UTR is shown as SEQ ID NO.4, the sequence of the polyA is shown as SEQ ID NO.5, and the IRES sequence is shown as SEQ ID NO.8.
[0028] One aspect of the present invention provides an expression cassette, characterized in that it comprises the recombinant nucleic acid or the recombinant mRNA.
[0029] One aspect of the present invention provides a vector, characterized in that it comprises the recombinant nucleic acid, or the recombinant mRNA, or the expression cassette; preferably, the vector comprises a self-replicating vector; more preferably, the self-replicating vector comprises a VEE self-replicating vector; most preferably, the sequence of the vector comprises the sequence shown in SEQ ID NO.7, SEQ ID NO.9, or SEQ ID NO.11.
[0030] One aspect of the present invention provides a cell, characterized in that it contains the recombinant nucleic acid, or the recombinant mRNA, or the expression cassette, or the vector.
[0031] One aspect of the present invention provides a recombinant bacterium, characterized in that it comprises the recombinant nucleic acid, or the recombinant mRNA, or the expression cassette, or the vector; preferably, the bacterium is Escherichia coli; more preferably, the Escherichia coli is one of E. coli BL21 (DE3), E. coli Origami B (DE3) or E. coli Rosetta Blue (DE3); most preferably, the E. coli is E. coli BL21 (DE3).
[0032] One aspect of the present invention provides a composition, characterized in that it comprises the BVDV antigen fragment, or the BVDV antigen fusion fragment, or the trivalent BVDV antigen fusion fragment, or the BVDV antigen fusion protein, or the recombinant nucleic acid, or the recombinant mRNA, or the expression cassette, or the vector, or the cell, or the recombinant bacteria.
[0033] One aspect of the present invention provides a kit, characterized in that it comprises the BVDV antigen fragment, or the BVDV antigen fusion fragment, or the trivalent BVDV antigen fusion fragment, or the BVDV antigen fusion protein, or the recombinant nucleic acid, or the recombinant mRNA, or the expression cassette, or the vector, or the cell, or the recombinant bacteria, or the composition.
[0034] One aspect of the present invention provides a trivalent BVDV mRNA vaccine comprising:
[0035] (a) the recombinant mRNA; and
[0036] (b) a pharmaceutically acceptable carrier; preferably, the carrier comprises lipids; more preferably, the lipids comprise one or more of cationic lipids, ionizable lipids, helper lipids, cholesterol, and DMG-PEG2000.
[0037] One aspect of the present invention provides a method for preparing a capped mRNA recombinant expression vector, a non-capped mRNA recombinant expression vector, or a self-replicating RNA recombinant expression vector that expresses recombinant trivalent BVDV mRNA, comprising the following steps:
[0038] Step a: synthesizing the gene fragment of the recombinant nucleic acid;
[0039] Step b: constructing a capped mRNA framework vector, constructing a non-capped mRNA framework vector, or constructing a VEE self-replicating vector;
[0040] The capped mRNA framework vector comprises a 5'-UTR, a 3'-UTR and a polyA sequence and a vector for fixing the capped mRNA framework, the sequences of which are shown in SEQ ID NO.3-6 respectively; or,
[0041] The non-capped mRNA framework vector comprises an IRES sequence, a 3'-UTR and a polyA sequence, and a vector for fixing the non-capped mRNA framework, wherein the sequence of IRES is shown as SEQ ID No. 8; or,
[0042] Constructing a VEE self-replicating vector: obtaining a self-replicating RNA sequence based on the genome of an alphavirus family; the self-replicating RNA sequence contains genes encoding the self-replicating components of the alphavirus and lacks genes for the structural proteins that produce infectious alphavirus particles; amplifying the plasmid obtained from the self-replicating RNA sequence as a template to synthesize the VEE self-replicating vector; the sequence of the VEE self-replicating vector is shown in SEQ ID NO. 10;
[0043] Step c: preparing a capped mRNA, non-capped mRNA or self-replicating RNA recombinant expression vector;
[0044] Inserting the gene synthesized in step a into a capped mRNA framework vector to obtain a capped mRNA recombinant expression vector. Preferably, the sequence of the capped mRNA recombinant expression vector is shown in SEQ ID NO.7; or,
[0045] Inserting the gene synthesized in step a into a non-capped mRNA framework vector to obtain a non-capped mRNA recombinant expression vector. Preferably, the sequence of the non-capped mRNA recombinant expression vector is shown in SEQ ID NO.9; or
[0046] Insert the gene synthesized in step a into the designated position of the VEE self-replicating vector to obtain a self-replicating RNA recombinant expression vector. Preferably, the sequence of the self-replicating RNA recombinant expression vector is shown in SEQ ID NO.11.
[0047] One aspect of the present invention provides a method for preparing a trivalent BVDV mRNA vaccine, comprising:
[0048] (a) providing the recombinant mRNA;
[0049] (b) mixing the mRNA with lipid particles and incubating the mixture to form lipid nanoparticles encapsulating the mRNA.
[0050] One aspect of the present invention provides a method for preparing a trivalent BVDV capped mRNA framework vector vaccine, a non-capped mRNA framework vector vaccine, or a self-replicating RNA structure vector vaccine, characterized in that it comprises the following steps:
[0051] Step a: linearizing the capped mRNA recombinant expression vector, the non-capped mRNA recombinant expression vector or the self-replicating RNA recombinant expression vector using a restriction endonuclease;
[0052] Step b: performing an in vitro co-transcription capping reaction on the linearized capped mRNA recombinant expression vector, adding a 7-methylated guanylate cap structure to the 5' end of the transcribed mRNA, and degrading the template DNA; or,
[0053] The linearized non-capped mRNA recombinant expression vector is subjected to an in vitro non-capped transcription reaction, and the template DNA is degraded; or,
[0054] The linearized self-replicating RNA recombinant expression vector is subjected to an in vitro co-transcription capping reaction to add a 7-methylated guanylate cap structure to the 5' end of the transcribed RNA, and the template DNA is degraded;
[0055] Step c: The capped, uncapped, and self-replicating mRNAs prepared in step b are mixed with lipids respectively, and the mRNA is encapsulated into LNP to obtain an mRNA-LNP complex. The formulation solution is prepared by concentration and liquid replacement, thereby obtaining the vaccine.
[0056] One aspect of the present invention provides the use of the BVDV antigen fragment, or the BVDV antigen fusion fragment, or the trivalent BVDV antigen fusion fragment, or the BVDV antigen fusion protein, or the recombinant mRNA in any of the following: (I) preparing a medicament for treating or preventing a disease caused by BVDV infection; or, (II) preparing a medicament for treating or preventing bovine viral diarrhea; or (III) preparing a medicament for inducing a specific immune response against BVDV in a subject.
[0057] The broad-spectrum anti-bovine viral diarrhea virus mRNA vaccine of the present invention has the following beneficial technical effects:
[0058] 1. The present invention uses a single mRNA to simultaneously express antigens from different BVDV genotypes, exhibiting strong immunogenicity and effective, high-level secretion in animals, thereby inducing higher levels of specific neutralizing antibodies against BVDV1a, BVDV1b, and BVDV2, and achieving ideal immune effects against BVDV genotypes such as BVDV1a, 1b, and 2. Thus, the trivalent BVDV mRNA vaccine of the present invention can effectively block cross-infection caused by multiple BVDV strains and reduce losses to the aquaculture industry.
[0059] 2. The antigen fusion protein of the present invention incorporates the IgG1 Fc domain, which promotes solubility and secretion. This significantly enhances the immunogenicity of the E2 protein and increases the production of neutralizing antibodies against BVDV in the body. Therefore, protective effects can be achieved with a lower vaccine dose. Consequently, reducing the vaccination dose also reduces the amount of liposomes used, thereby reducing the cytotoxicity of the liposomes, thereby reducing the toxicity of the vaccine while maintaining the immune effect.
[0060] 3. The mRNA-based vaccine of the present invention has a strong immune response in mouse experiments, and mRNA itself has an adjuvant effect, so it can induce a significant immune response.
[0061] 4. The present invention relates to a trivalent BVDV mRNA vaccine, which is synthesized by in vitro enzymatic transcription reaction using linearized plasmid DNA as a template. This synthesis strategy avoids the production method of living cell culture and does not need to consider safety and complex production processes.
[0062] 5. The trivalent BVDV mRNA vaccine of the present invention involves a universal mRNA vaccine platform, which can select new antigen sequences based on the annual or seasonal variation of the strain and quickly develop new vaccines without changing the process flow. BRIEF DESCRIPTION OF THE DRAWINGS
[0063] Figure 1 is a schematic diagram of the structure of the BVDV trivalent vaccine of the present invention, a schematic diagram of the structure of BVDV antigen fusion protein mRNA, i.e., secretion signal peptide + bovine IgG1 Fc + BVDV1a E2 protein domain I-II + BVDV1b E2 protein domain I-II + BVDV2 E2 protein domain I-II.
[0064] Figures 2A-2D are Western Blot and Dotblot test results of the BVDV antigen fusion protein mRNA of the present invention and the control, wherein Figure 2A is a Dot blot protein expression diagram of the mRNA of the present invention, i.e., secretion signal peptide + bovine IgG1 Fc + BVDV1a domain I-II + BVDV1b domain I-II + BVDV2 domain I-II, after in vitro transfection of HEK293T cells; Figure 2B is a Western Blot protein expression diagram of bovine IgG1 Fc + BVDV1a domain I-II + BVDV1b domain I-II + BVDV2 domain I-II after in vitro transfection of the mRNA of the present invention into HEK293T cells; Figure 2C is a Western Blot protein expression diagram of the mRNA of the present invention (Fc+) and the control (not containing bovine IgG1 FIG2D is a Western Blot protein expression graph after HEK293T cells were transfected with the mRNA of the present invention (Fc+) and the control (not containing bovine IgG1 Fc, i.e., Fc-) in vitro; FIG2E is a Dot blot protein expression graph after HEK293T cells were transfected with the mRNA of the present invention (Fc+) and the control (not containing bovine IgG1 Fc, i.e., Fc-) in vitro.
[0065] FIG3 is a schematic diagram of the BVDV antigen fusion protein mRNA mouse immunization and sampling process of the present invention.
[0066] FIG4 is a schematic diagram of the spatial structure of the BVDV E2 domain I-II of the present invention, with reference to the BVDV E2 protein structure (PDB: 4ILD). DETAILED DESCRIPTION
[0067] Definitions and Terminology
[0068] The term "bovine" refers to bovine animals including, but not limited to, cattle, bulls, heifers, cows, and calves. As used herein, bovine refers to both pregnant and lactating bovine animals. Preferably, the methods of the present invention are administered to non-human mammals; preferably, lactating or pregnant cows and their fetuses or lactating calves.
[0069] The term "BVDV" refers to bovine viral diarrhea virus, also known as bovine viral diarrhea virus. BVDV has two main genotypes: BVDV1 and BVDV2. BVDV1 is the classic strain, primarily causing diarrhea and clinically detected at a significantly higher rate than BVDV2. While BVDV2 can also cause diarrhea, it is more virulent and can cause acute illness, thrombocytopenia, and hemorrhagic syndrome in adult cattle. BVDV1 includes genotypes such as BVDV1a and BVDV1b.
[0070] The term "immunogenic" refers to the ability of BVDV to elicit an immune response in an animal against BVDV type 1 or type 2, or against both BVDV type 1 and type 2. The immune response can be a cellular immune response mediated primarily by cytotoxic T cells or a humoral immune response mediated primarily by helper T cells, thereby activating B cells and leading to antibody production.
[0071] The term "administration" or "vaccination" means that the mRNA, vaccine composition of the present invention is preferably administered to cattle via an intramuscular or subcutaneous route, although other routes of administration can also be used, such as, for example, oral, intranasal (e.g., aerosol or other non-injectable administration), intralymph node, intradermal, intraperitoneal, rectal or vaginal administration, or a combination thereof. Administration into the animal's neck muscle is preferred. Boosting regimens can be used and the administration regimen can be adjusted to provide optimal immunity.
[0072] The term "expression" includes any step involved in the production of the polypeptide including, but not limited to, transcription, post-transcriptional modification, translation, post-translational modification, and secretion.
[0073] The term "recombinant nucleic acid molecule" refers to a polynucleotide having sequences that are not linked together in nature. The recombinant polynucleotide can be included in a suitable vector, and the vector can be used to transform into a suitable host cell. The polynucleotide is then expressed in the recombinant host cell to produce, for example, a "recombinant polypeptide," "recombinant protein," "fusion protein," and the like.
[0074] The term "recombinant expression vector" refers to a DNA construct used to express, for example, a polynucleotide encoding a desired polypeptide. A recombinant expression vector may include, for example, a collection of genetic elements that regulate gene expression, such as promoters and enhancers; (2) a structural or coding sequence that is transcribed into mRNA and translated into protein; and (3) appropriate transcription and translation initiation and termination sequences. Recombinant expression vectors are constructed in any suitable manner. The nature of the vector is not important, and any vector may be used, including plasmids, viruses, phages, and transposons. Possible vectors for use in the present disclosure include, but are not limited to, chromosomal, non-chromosomal, and synthetic DNA sequences, such as viral plasmids, bacterial plasmids, phage DNA, yeast plasmids, and vectors derived from combinations of plasmids and phage DNA, DNA from viruses such as lentiviruses, retroviruses, vaccinia, adenoviruses, fowlpox, baculoviruses, SV40, and pseudorabies. Self-replicating and non-self-replicating vectors are included.
[0075] The term "mRNA" refers to messenger RNA, which is translated into "messenger ribonucleic acid" in Chinese. It is a type of single-stranded ribonucleic acid that is transcribed from a chain of DNA as a template, carries genetic information and can guide protein synthesis.
[0076] The term "BVDV mRNA vaccine" includes vaccines targeting different BVDV genotypes based on mRNA, including conventional mRNA or self-replicating mRNA. Existing mRNA vaccine platform technologies have two main routes: one based on conventional mRNA and the other based on self-replicating mRNA; both routes can be applied to the present invention. Self-replicating mRNA vaccines, after being inoculated into animals, can replicate their own sequences using themselves as a template. Therefore, compared to conventional mRNA vaccines, the required inoculation dose is smaller, and the adjuvant effect formed by the immune response induced during self-replication can induce a stronger immune response, further enhancing humoral and cellular immune responses.
[0077] The term "BVDV mRNA vaccine preparation method" includes the preparation of mRNA using linearized plasmid DNA as a template and an in vitro enzymatic transcription reaction. The linearized plasmid DNA uses T7 RNA polymerase to initiate the in vitro transcription reaction, and the template DNA is degraded using DNase enzyme, and the restriction endonuclease is SapI / BspQI enzyme. The prepared mRNA and lipids (composed of cationic lipids / ionizable lipids, auxiliary lipids, cholesterol and DMG-PEG2000) are rapidly mixed in a mixer, thereby causing the precipitation of lipids and the encapsulation of mRNA into LNPs under the action of charge. The mRNA-LNP complex is then concentrated and the solution is exchanged into a paper solution.
[0078] The term "BVDV mRNA vaccine application method" includes the application method of a broad-spectrum mRNA-based bovine viral diarrhea virus vaccine using a prime-boost administration method. The prime-boost administration method uses mRNA-secretionary signal peptide + bovine IgG1 Fc + BVDV1a domains I-II + BVDV1b domains I-II + BVDV2 domains I-II. The vaccine is administered as a first injection and booster injections, and the number of booster injections is determined as needed.
[0079] The term "5'-UTR" refers to the "5' untranslated region" or "5'UTR", which is a portion of a gene that is transcribed into a primary RNA transcript (pre-mRNA) and is located upstream of the coding sequence. The primary transcript is the initial RNA product, containing introns and exons, produced by transcription from DNA. Many primary transcripts must undergo RNA processing to form physiologically active RNA. The processing steps to form mature mRNA include modifying the ends, removing introns, capping and / or cleaving individual rRNA molecules from the precursor RNA. Therefore, the 5'UTR of an mRNA is the portion of the mRNA that is not translated into protein and is located upstream of the coding sequence. In a genomic sequence, the 5'UTR is generally defined as the region located between the transcription start site and the start codon. The 5' untranslated region (5'UTR) of vertebrate mRNA can be from tens to hundreds of bases in length.
[0080] The term "3'-UTR", which refers to a "3'-untranslated region" or "3'UTR", relates to a region located at the 3' end of a gene, downstream of the stop codon of the protein coding region, and which is transcribed but not translated into an amino acid sequence, or to the corresponding region in an RNA molecule. The 3'-untranslated region typically extends from the stop codon of the translation product to a poly(A) sequence that is typically attached after the transcription process. The 3'-untranslated region of mammalian mRNA typically has a homology region known as the AAUAAA hexanucleotide sequence. This sequence may be a poly(A) attachment signal and is often located 10 to 30 bases upstream of the poly(A) attachment site. The 3'-untranslated region may contain one or more inverted repeats that may fold to create a stem-loop structure that acts as a barrier to exoribonucleases or interacts with proteins known to increase RNA stability, such as RNA binding proteins.
[0081] The term "polyA," meaning "polyadenylic acid sequence," "poly(A) sequence," or "poly(A) tail," refers to a sequence of adenylate residues typically located at the 3' end of an RNA molecule. The present invention allows for the attachment of such a sequence during RNA transcription by a DNA template based on repeated thymidylate residues in the strand complementary to the coding strand, whereas the sequence is not normally encoded in DNA but is attached to the free 3' end of the RNA by a template-independent RNA polymerase after transcription in the nucleus.
[0082] The term "host cell" refers to a cell into which an exogenous polynucleotide has been introduced, including the progeny of such cells. Host cells include "transformants" and "transformed cells," which include primary transformed cells and progeny derived therefrom. Host cells are any type of cell system that can be used to produce the mRNA of the present invention, including eukaryotic cells, for example, mammalian cells, insect cells, yeast cells; and prokaryotic cells, for example, Escherichia coli cells. Host cells include cultured cells.
[0083] The term "recombinant host cell" encompasses host cells that are transformed from their parental cells after introduction of a recombinant nucleic acid molecule, recombinant expression vector, or mRNA. Recombinant host cells are specifically achieved by transformation. The host cells disclosed herein can be prokaryotic or eukaryotic, and primarily, any cell capable of introducing the recombinant nucleic acid molecule, recombinant expression vector, mRNA, etc. disclosed herein is sufficient.
[0084] The terms "transformation, transfection, and transduction" have the meanings generally understood by those skilled in the art, namely, the process of introducing exogenous DNA or RNA into a host.
[0085] The term "treating" refers to reducing or eliminating BVDV types 1 and 2. After a subject has contracted a disease, exposing (e.g., administering) the mRNA, composition, etc. of the present invention to a subject may alleviate the symptoms of the disease compared to a patient without such exposure. This does not necessarily mean that the symptoms of the disease are completely suppressed. Contracting a disease means that the symptoms of the disease appear in the body.
[0086] The term "prevent" means reducing or eliminating BVDV types 1 and 2. Exposure (e.g., administration) of the mRNA, composition, etc. of the present invention to a subject before the subject develops a disease may alleviate symptoms after the subject develops the disease compared to a condition without exposure, but does not necessarily mean that the disease is completely suppressed.
[0087] The term "effective amount" refers to an amount or dosage of a recombinant nucleic acid molecule, recombinant expression vector, mRNA, vaccine, or composition of the present invention that, upon administration to a subject in single or multiple doses, produces the desired effect in a patient in need of treatment or prevention. An effective amount can be readily determined by a skilled artisan by considering a variety of factors, such as the species of mammal; size, age, and health; the specific disease involved; the extent or severity of the disease; the response of the individual patient; the specific antibody administered; the mode of administration; the bioavailability characteristics of the administered formulation; the dosing regimen selected; and the use of any concomitant therapy.
[0088] The term "pharmaceutically acceptable carrier" refers to auxiliary materials widely used in the field of drug production. The main purpose of using a carrier is to provide a pharmaceutical composition that is safe to use, stable in nature and / or has specific functionality, and also to provide a method so that it can be effectively absorbed in the body of a subject. A pharmaceutically acceptable carrier can be an inert filler or an effective component that provides a certain function to the pharmaceutical composition (for example, stabilizing the overall pH value of the composition or preventing the degradation of the active ingredient in the composition). Non-limiting examples of pharmaceutically acceptable carriers include, but are not limited to, adhesives, suspending agents, emulsifiers, diluents (or fillers), granulating agents, adhesives, disintegrants, lubricants, anti-adhesives, glidants, gelling agents, absorption delaying agents, dissolution inhibitors, enhancers, adsorbents, buffers, chelating agents, preservatives, colorants, flavorings and sweeteners.
[0089] The term "veterinary-acceptable carrier" includes any and all solvents, dispersants, coating agents, adjuvants, stabilizers, diluents, preservatives, antibacterial and antifungal agents, isotonic agents, adsorption delay agents, and the like. Diluents may include water, saline, dextrose, ethanol, glycerol, and the like. Isotonic agents may include sodium chloride, dextrose, mannitol, sorbitol, and lactose. Stabilizers may include albumin, and the like. Adjuvants include, but are not limited to, the RIBI adjuvant system (Ribi Inc.), alum, aluminum hydroxide gel, cholesterol, oil-in-water emulsions, water-in-oil emulsions such as, for example, Freund's complete and incomplete adjuvants, Block Co-polymer (CytRx, Atlanta GA), SAF-M (Chiron, Emeryville CA), AMPHIGEN adjuvant, saponins, Quil A, QS-21 (Cambridge Biotech Inc., Cambridge MA), GPI-0100 (Galenica Pharmaceuticals, Inc., Birmingham, AL) or other saponin fractions, monophosphoryl lipid A, avridine lipid-amine adjuvant, Escherichia coli heat-labile toxin (recombinant or otherwise), cholera toxin, or muramyl dipeptide. The immunogenic composition can further include one or more other immunomodulators such as, for example, interleukins, interferons, or other cytokines.
[0090] Unless defined otherwise or clearly indicated by the context, all technical and scientific terms in this disclosure have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs.
[0091] The present invention discloses mRNA-based vaccines targeting different BVDV genotypes and methods for their preparation. Those skilled in the art can refer to the content herein and appropriately modify the process parameters to achieve the desired results. It is particularly important to note that all similar substitutions and modifications will be apparent to those skilled in the art and are considered encompassed by the present invention. The methods and applications of the present invention have been described through preferred embodiments, and it is apparent that those skilled in the art can modify or appropriately alter and combine the methods and applications described herein to implement and apply the technology of the present invention without departing from the content, spirit, and scope of the present invention.
[0092] In the mRNA-based vaccine against bovine viral diarrhea virus and the preparation method thereof provided by the present invention, the raw materials and reagents used can be obtained commercially.
[0093] The present invention is further illustrated below with reference to the following examples. Preferably, a conventional capped mRNA architecture is used for the preparation of a BVDV vaccine. Conventional capped mRNA is synthesized in vitro by an enzymatic co-transcriptional capping reaction using linearized plasmid DNA as a template.
[0094] Example 1 Synthesis of gene fragments containing secretory signal peptide + bovine IgG1 Fc + BVDV1a domain I-II + BVDV1b domain I-II + BVDV2 domain I-II and vector construction
[0095] The E2 protein genes of various mutant strains of the BVDV 1a, 1b, and 2 genotypes were searched from NCBI. Sequence alignments were performed on the E2 proteins of the different genotypes to identify the E2 protein sequence with the least divergence. Based on the reported BVDV E2 protein structure, the E2 domains I-II were extracted. The secretory signal peptide and Fc fragment of bovine IgG1 were selected. These protein domain sequences were combined to produce an antigen fusion protein (from N-terminus to C-terminus): bovine IgG1 secretory signal peptide + bovine IgG1 Fc fragment + BVDV 1a E2 protein domains I-II + BVDV 1b E2 protein domains I-II + BVDV 2 E2 protein domains I-II. A 6×His tag was attached to the C-terminus for expression detection. The sequence was then optimized based on codon degeneracy, and finally the DNA sequence (sequence shown in SEQ ID NO.2) was directly obtained by synthesis (commissioned to KingScript for synthesis), and the synthesized target gene was finally inserted into the multiple cloning site of the pUC57 vector to obtain the plasmid CS-BVDV-210. The amino acid sequence encoding the BVDV antigen fusion protein polypeptide is shown in SEQ ID NO.1. Figure 1 shows a schematic diagram of the structure of the BVDV trivalent vaccine of the present invention, a schematic diagram of the BVDV antigen fusion protein mRNA, i.e., a secretion signal peptide + bovine IgG1 Fc + BVDV1a E2 protein domain I-II + BVDV1b E2 protein domain I-II + BVDV2 E2 protein domain I-II structure map.
[0096] The following vectors (I) to (III) were prepared based on the gene fragment encoding the BVDV antigen fusion protein.
[0097] (I) Conventional capped mRNA preparation vector
[0098] Step a: Synthesize signal peptide-bovine IgG1 Fc fragment-BVDV1a E2 domain I-II-BVDV1b E2 domain I-II-BVDV2 E2 domain I-II gene fragment;
[0099] Step b: Construction of capped mRNA construct vector
[0100] The capped mRNA framework vector comprises 5'-UTR, 3'-UTR and polyA sequence and a vector pUC57 for fixing the capped mRNA framework, the sequences of which are shown in SEQ ID NO.3-6 respectively;
[0101] Step c: preparing the recombinant plasmid CS-BVDV-210;
[0102] The gene synthesized in step a was inserted into the capped mRNA framework vector pUC57 to obtain plasmid CS-BVDV-210. The sequence of the plasmid CS-BVDV-210 is shown in SEQ ID NO.7.
[0103] (II) Non-capped mRNA preparation vector
[0104] Step a: Synthesize the target gene as in step (I) above;
[0105] Step b: constructing a non-capped mRNA framework vector;
[0106] The non-capped mRNA framework vector comprises an IRES sequence, a 3'-UTR and a polyA sequence, as well as a vector for fixing the non-capped mRNA framework, wherein the IRES sequence is shown as SEQ ID NO.8.
[0107] Step c: preparing the recombinant plasmid CS-BVDV-220;
[0108] The gene synthesized in step a was inserted into a non-capped mRNA framework vector to obtain plasmid CS-BVDV-220; the sequence of the plasmid CS-BVDV-220 is shown in SEQ ID NO.9.
[0109] (III) Self-replicating RNA framework vector
[0110] Step a: Synthesize the target gene as in step (I) above;
[0111] Step b: constructing a VEE self-replicating vector;
[0112] A self-replicating RNA sequence is obtained from the genome of an alphavirus family; the self-replicating RNA sequence comprises genes encoding alphavirus self-replicating components and lacks genes encoding structural proteins that produce infectious alphavirus particles; a plasmid constructed from the self-replicating RNA sequence is used as a template for amplification to obtain the VEE self-replicating vector by synthesis; the sequence of the VEE self-replicating vector is shown in SEQ ID NO. 10;
[0113] Step c: preparing the recombinant plasmid CS-BVDV-230;
[0114] The gene synthesized in step a is inserted into the designated position of the VEE self-replicating vector to obtain the recombinant plasmid CS-BVDV-230; the sequence of the plasmid CS-BVDV-230 is shown in SEQ ID NO.11.
[0115] Control system: obtained by removing the bovine IgG1 Fc sequence from plasmid CS-BVDV-210, wherein the bovine IgG1 Fc nucleic acid sequence is shown in SEQ ID No. 12).
[0116] Table 1 BVDV antigen fusion protein polypeptides and related sequences
[0117] Example 2 Preparation of different types of mRNA vaccines
[0118] (I) Preparation of capped mRNA-based vector vaccines
[0119] Step a: linearize the plasmid CS-BVDV-210 using restriction endonucleases;
[0120] Step b: performing an in vitro co-transcription capping reaction on the linearized CS-BVDV-210 plasmid to add a 7-methylated guanylate cap structure to the 5' end of the transcribed mRNA, and degrading the template DNA;
[0121] (II) Preparation of vaccines based on non-capped mRNA architecture vectors
[0122] Step a: linearize the plasmid CS-BVDV-220 using restriction endonucleases;
[0123] Step b: performing an in vitro non-capped transcription reaction on the linearized CS-BVDV-220 plasmid and degrading the template DNA;
[0124] (III) Preparation of vaccines based on self-replicating RNA structures
[0125] Step a: linearize the CS-BVDV-230 plasmid using restriction endonucleases;
[0126] Step b: The linearized CS-BVDV-230 plasmid is subjected to an in vitro co-transcription capping reaction to add a 7-methylated guanylate cap structure to the 5' end of the transcribed RNA, and the template DNA is degraded;
[0127] The mRNAs prepared in (I-III) are mixed with lipids respectively, and the mRNAs are encapsulated into LNPs to obtain mRNA-LNP complexes. The formulation solutions are prepared by concentration and liquid replacement, thereby obtaining the vaccine.
[0128] Example 3: Linearization of Plasmid CS-BVDV-210 and Control System and In Vitro Co-transcription and Capping to Prepare mRNA. The plasmid CS-BVDV-210 and control system described in Example 1 were linearized using BspQI digestion, and the linearized CS-BVDV-210 and control were recovered using magnetic bead purification. 1% agarose gel electrophoresis was performed to check whether the plasmids CS-BVDV-210 and control were completely linearized.
[0129] After linearization, CS-BVDV-210 and a control plasmid were used to initiate in vitro transcription using T7 RNA polymerase. A cap analog, 7-methylated guanylate cap structure, was added directly to the in vitro transcription reaction, resulting in mRNAs containing the cap analog at their 5' end. Following in vitro transcription, the template DNA was degraded using DNase.
[0130] Example 4 mRNA-secretion signal peptide + bovine IgG1 Fc + BVDV1a domain I-II + BVDV1b domain I-II + BVDV2 domain I-II and control system and lipid encapsulation
[0131] The mRNA of the present invention and the control system described in Example 1 were mixed with the following lipids: the ionizable lipid DHA-1 (Sinobon, Catalog No. 0604000930), the auxiliary lipid DSPC (Sinobon, Catalog No. 06030001100), cholesterol (Avitol, 57-88-5), and DMG-PEG2000 (Sinobon, Catalog No. 06020112402). The molar ratio of the four lipids was 50:10:38.5:1.5 for DHA-1:DSPC:cholesterol:DMG-PEG2000. The molar ratio of the mRNA to the LNP (total of the four lipids) was 1:5. The components were dissolved in anhydrous ethanol and rapidly mixed in a mixer, causing precipitation of the lipids and encapsulation of the mRNA into the LNPs under the action of the charge. The mRNA-LNP complex was then concentrated and the solution was exchanged to prepare the formulation solution.
[0132] Example 5 Western Blot and Dot Blot Detection of mRNA Expression and Secretion in Cells
[0133] HEK293T cells were subcultured and, when sufficient cells were present, trypsinized and plated into each well of a 6-well cell culture plate. The plates were then plated and cultured overnight at 37°C in a CO2 incubator. The next day, liposome-encapsulated mRNA was transfected into the plated HEK293T cells. After 48 hours of culture, the cell lysate and supernatant culture medium were collected.
[0134] 1) Western Blot Detection:
[0135] Electrophoresis: The concentration of polyacrylamide separation gel was 12%, the protein loading amount was 40 μg, the electrophoresis conditions of the stacking gel were 90 V, and the electrophoresis conditions of the separation gel were 120 V.
[0136] Transfer: Use PVDF membrane for transfer at 100V for 1h.
[0137] Blocking: Use 5% BSA prepared in 1xTBST as blocking solution and block for 1 hour.
[0138] Primary antibody incubation: Dilute 6×His antibody at 1:2500 in blocking buffer and incubate overnight at 4°C.
[0139] Secondary antibody incubation: dilute the corresponding secondary antibody in blocking buffer at a dilution ratio of 1:5000 and incubate at room temperature for 1 hour.
[0140] Development: Developing solution A:B = 1:1, and develop in an imaging system.
[0141] 2) Dot blot detection:
[0142] 100 μl of the recovered supernatant culture medium was added dropwise onto the PVDF membrane; after it dried, 5% BSA prepared in 1×TBST was used as a blocking solution and blocked for 1 hour.
[0143] Primary antibody incubation: Dilute 6×His antibody at 1:2500 in blocking buffer and incubate overnight at 4°C.
[0144] Secondary antibody incubation: dilute the corresponding secondary antibody in blocking buffer at a dilution ratio of 1:5000 and incubate at room temperature for 1 hour.
[0145] Development: Developing solution A:B = 1:1, and develop in an imaging system.
[0146] The experimental results are shown in Figures 2A-2D, which are Western Blot and Dot blot detection results of the BVDV antigen fusion protein mRNA of the present invention and the control, wherein Figure 2A is a Dot blot protein expression diagram of the mRNA of the present invention, i.e., secretion signal peptide + bovine IgG1 Fc + BVDV1a domain I-II + BVDV1b domain I-II ++ BVDV2 domain I-II, after in vitro transfection of HEK293T cells, bovine IgG1 Fc + BVDV1a domain I-II + BVDV1b domain I-II ++ BVDV2 domain I-II; Figure 2B is a Western Blot protein expression diagram of bovine IgG1 Fc + BVDV1a domain I-II + BVDV1b domain I-II ++ BVDV2 domain I-II after the mRNA of the present invention was transfected into HEK293T cells in vitro; Figure 2C is a Western Blot protein expression diagram of the mRNA of the present invention (Fc+) and the control (not containing bovine IgG1 FIG2D is a Western Blot protein expression graph after HEK293T cells were transfected with the mRNA of the present invention (Fc+) and the control (not containing bovine IgG1 Fc, i.e., Fc-) in vitro; FIG2E is a Dot blot protein expression graph after HEK293T cells were transfected with the mRNA of the present invention (Fc+) and the control (not containing bovine IgG1 Fc, i.e., Fc-) in vitro.
[0147] Figures 2A and 2B show protein expression of bovine IgG1 Fc + BVDV1a domain I-II + BVDV1b domain I-II + BVDV2 domain I-II after in vitro mRNA transfection into HEK293T cells. Western blot (WB) and Dot Blot (Figure 2A) results demonstrate efficient expression and secretion of the corresponding target proteins after in vitro transfection into cells. Figures 2A and 2B demonstrate that bovine IgG1 Fc + BVDV1a domain I-II + BVDV1b domain I-II + BVDV2 domain I-II protein expression and secretion are excellent after in vitro transfection into HEK293T cells with mRNA-bovine IgG1 Fc + BVDV1a domain I-II + BVDV1b domain I-II + BVDV2 domain I-II.
[0148] In addition, Figures 2C and 2D show that the control without bovine IgG1 Fc has very low secretion expression compared to the mRNA of the present invention, confirming that the bovine IgG1 Fc domain added to the mRNA of the present invention plays a crucial role in the expression and secretion of the target protein polypeptide BVDV antigen fusion protein.
[0149] Example 6 Detection of anti-BVDV neutralizing antibodies induced in mice immunized with mRNA-bovine IgG1 Fc+BVDV1a domain I-II+BVDV1b domain I-II++BVDV2 domain I-II vaccine
[0150] After 7 days of adaptive feeding, 6-8 week old BALB / c female mice were given the mRNA-LNP complex prepared in Example 4 (comprising mRNA-bovine IgG1 Fc + BVDV1a domain I-II + BVDV1b domain I-II + BVDV2 domain I-II) in 5 mice, and 5 mice were given the control group (no dosing measures were taken, only blood was collected for comparative analysis). The administration method was subcutaneous injection in the groin. Each group of animals was immunized 3 times, on day 0 (D0), day 14 (D14), and day 28 (D28), with a dose of 10ug mRNA-LNP / mouse / time. Figure 3 shows a schematic diagram of the BVDV antigen fusion protein mRNA mouse immunization and sampling process of the present invention.
[0151] Figure 3 is a schematic diagram of the BVDV antigen fusion protein mRNA mouse immunization and sampling process of the present invention, which shows that the blood sampling time points are D7 / D14 / D21 / D28 / D35 / D42, and each mouse whole blood is taken at least 100 μl at each blood sampling, so as to meet the requirement of serum reaching 50 μl. Five mice are fixed as one biological sample group, and the serum extracted from the five mice in each group is mixed into one biological sample (250 μl). Therefore, one sample is obtained after each sampling of each sample group.
[0152] The neutralizing antibody titer detection method is ELISA, and the specific operation is as follows:
[0153] MDBK cells were trypsinized and adjusted to 2×10 5 cells / mL with DMEM medium containing 10% fetal bovine serum; the cells were evenly plated into a 96-well cell culture plate at 100 μl / well and cultured in a 37° C. CO 2 incubator overnight.
[0154] The test serum was inactivated at 56°C for 30 minutes, centrifuged at 10,000 g for 10 minutes, and serially diluted twofold starting at 1:8 in DMEM medium containing 2% fetal bovine serum. Suspensions of different BVDV subtypes (BVDV1a: NADL strain (GenBank ID: AJ133738.1), BVDV 1b: JS2201 strain (GenBank ID: OP856581), and BVDV2: C201602 (GenBank ID: MG420995)) were diluted to an inoculum of 100 TCID50 / 50 μl in DMEM containing 2% fetal bovine serum. Equal volumes of the virus suspension were mixed with the test serum at different dilutions and incubated at 37°C for 1 hour. The incubated mixture was then added to MDBK cells in a 96-well cell culture plate, with 100 μl per well. Four replicates were prepared for each sample. At the same time, positive and negative serum controls (1:8 dilution), blank controls, and infected cell controls were set up and cultured in a cell incubator for 5 days.
[0155] Detection was performed by indirect immunofluorescence assay, and the specific steps were as follows:
[0156] The culture medium was discarded, and the cells were fixed with immunostaining fixative at room temperature for 20 minutes. The cells were washed three times with PBST and blocked with immunostaining blocking solution at 37°C for 1 hour. The cells were washed three times with PBST. BVDV monoclonal antibody (AHVLA, 1:100 dilution) was added at 100 μl / well and incubated at 37°C for 1 hour. The cells were washed three times with PBST. FITC-labeled goat anti-mouse IgG, 1:500 dilution, was added at 100 μl / well and incubated at 37°C for 1 hour. The cells were washed three times with PBST and observed under a fluorescence microscope. The number of positive and negative cell wells was counted, and the neutralizing antibody titer was calculated according to the Reed-Muench method.
[0157] Experimental Results: Neutralizing antibody titers in mouse sera against BVDV genotypes 1a, 1b, and 2. Table 2 shows the antibody test results (BVDV-1a); Table 3 shows the antibody test results (BVDV-2); and Table 4 shows the antibody test results (BVDV-1b).
[0158] Table 2 Antibody test results (BVDV-1a type)
[0159] Table 3 Antibody test results (BVDV-2 type)
[0160] Table 4 Antibody test results (BVDV-1b type)
[0161] Note: In Table 2-4, / means not tested
[0162] As can be seen from the results in Tables 2 to 4, mRNA-bovine IgG1 Fc+BVDV1a domain I-II+BVDV1b domain I-II+BVDV2 domain I-II can induce high levels of neutralizing antibodies in animals. In this example, the research subjects selected were mice. However, it can be inferred that the Fc fragment expressed by the mRNA is derived from bovine IgG1, and the protein fused to the Fc can increase the half-life of the fusion protein in cattle, further amplifying the induced immune response in cattle. In addition, the experimental results of this example show that the trivalent BVDV mRNA vaccine obtained by the method of the present invention can be well expressed in mice and induces a relatively significant neutralizing antibody titer. The present invention can simultaneously express antigens of multiple BVDV genotypes by using one mRNA, has strong immunogenicity and significant immune effects, and therefore has good application prospects.
[0163] The above embodiments of the present disclosure are merely examples for clearly illustrating the present disclosure, and are not intended to limit the embodiments of the present disclosure. For those skilled in the art, other variations or changes in different forms can be made based on the above description. It is not necessary and impossible to list all the embodiments here. Any modifications, equivalent substitutions, and improvements made within the spirit and principles of the present disclosure shall be included in the scope of protection of the claims of the present disclosure.
Claims
1. A BVDV antigen fragment, characterized in that: It comprises two immunoglobulin-like (Ig-like) domains near the N-terminus of the BVDV E2 protein, namely, BVDV E2 protein domains I-II; the immunoglobulin-like domains have self-stabilizing characteristics, and the spatial structure formed by them is not affected by the upstream and downstream sequences; the immunoglobulin-like domains contain a β-sheet structure with a Greek key topological conformation.
2. The BVDV antigen fragment according to claim 1, characterized in that It comprises one or more of BVDV1a E2 protein domains I-II, BVDV1b E2 protein domains I-II, and / or BVDV2 E2 protein domains I-II.
3. A BVDV antigen fusion fragment, characterized in that: It comprises an IgG1 Fc fragment fused to one or more of the BVDV1a E2 protein domains I-II, the BVDV1b E2 protein domains I-II and / or the BVDV2 E2 protein domains I-II.
4. The antigen fusion fragment according to claim 3, characterized in that: The IgG1 Fc fragment is a bovine IgG1 Fc fragment.
5. A trivalent BVDV antigen fusion fragment, characterized in that: Contains IgG1 Fc fragment, BVDV1a E2 protein domains I-II, BVDV1b E2 protein domains I-II, and BVDV2 E2 protein domains I-II.
6. The trivalent BVDV antigen fusion fragment according to claim 5, characterized in that: The trivalent BVDV antigen fusion fragment comprises, from N-terminus to C-terminus, a bovine IgG1 Fc fragment, BVDV1a E2 protein domains I-II, BVDV1b E2 protein domains I-II, and BVDV2 E2 protein domains I-II.
7. The trivalent BVDV antigen fusion fragment according to claim 5 or 6, characterized in that: The trivalent BVDV antigen fusion fragment also comprises a secretion signal peptide.
8. A BVDV antigen fusion protein, characterized in that: Contains any of the following sequences: (I) the amino acid sequence shown in SEQ ID NO.1; (II) an amino acid sequence obtained by substituting, deleting or adding one or more amino acid residues of the amino acid sequence shown in SEQ ID NO.1, and having the same function as the amino acid sequence shown in (I); or, (III) an amino acid sequence having at least 90% sequence identity with the sequence described in (I) or (II), and having the same function as the amino acid sequence shown in (I).
9. A recombinant nucleic acid, characterized in that The method comprises a nucleic acid encoding the BVDV antigen fragment according to claim 1 or 2, or the BVDV antigen fusion fragment according to claim 3 or 4, or the trivalent BVDV antigen fusion fragment according to any one of claims 5 to 7, or the BVDV antigen fusion protein according to claim 8.
10. The recombinant nucleic acid according to claim 9, characterized in that Contains any of the following sequences: (I) the nucleic acid sequence shown in SEQ ID NO.2; (II) a nucleic acid sequence obtained by replacing, deleting or adding one or more nucleotides of the nucleic acid sequence shown in SEQ ID NO. 2, and having the same function as the nucleic acid sequence shown in (I); or, (III) a nucleic acid sequence having at least 90% sequence identity with the sequence described in (I) or (II), and having the same function as the nucleic acid sequence shown in (I).
11. A recombinant mRNA, characterized in that The method comprises mRNA encoding the BVDV antigen fragment according to claim 1 or 2, or the BVDV antigen fusion fragment according to claim 3 or 4, or the trivalent BVDV antigen fusion fragment according to any one of claims 5 to 7, or the BVDV antigen fusion protein according to claim 8.
12. The recombinant mRNA according to claim 11, characterized in that The mRNA further comprises one or more of a 5'-UTR, a 3'-UTR, a polyA sequence, and an IRES sequence.
13. The recombinant mRNA according to claim 12, characterized in that The sequence of the 5'-UTR is shown in SEQ ID NO.3, the sequence of the 3'-UTR is shown in SEQ ID NO.4, the sequence of the polyA is shown in SEQ ID NO.5, and the sequence of the IRES is shown in SEQ ID NO.
8.
14. An expression cassette, characterized in that Comprising the recombinant nucleic acid according to claim 9 or 10, or the recombinant mRNA according to any one of claims 11-13.
15. A carrier, characterized in that Comprising the recombinant nucleic acid of claim 9 or 10, or the recombinant mRNA of any one of claims 11-13, or the expression cassette of claim 14.
16. A cell, characterized in that Comprising the recombinant nucleic acid of claim 9 or 10, or the recombinant mRNA of any one of claims 11-13, or the expression cassette of claim 14, or the vector of claim 15.
17. A recombinant bacterium, characterized in that: Comprising the recombinant nucleic acid of claim 9 or 10, or the recombinant mRNA of any one of claims 11-13, or the expression cassette of claim 14, or the vector of claim 15.
18. A composition, characterized in that The method comprises the BVDV antigen fragment according to claim 1 or 2, or the BVDV antigen fusion fragment according to claim 3 or 4, or the trivalent BVDV antigen fusion fragment according to any one of claims 5 to 7, or the BVDV antigen fusion protein according to claim 8, or the recombinant nucleic acid according to claim 9 or 10, or the recombinant mRNA according to any one of claims 11 to 13, or the expression cassette according to claim 14, or the vector according to claim 15, or the cell according to claim 16, or the recombinant bacterium according to claim 17.
19. A kit, characterized in that: Comprising the BVDV antigen fragment of claim 1 or 2, or the BVDV antigen fusion fragment of claim 3 or 4, or the trivalent BVDV antigen fusion fragment of any one of claims 5-7, or the BVDV antigen fusion protein of claim 8, or the recombinant nucleic acid of claim 9 or 10, or the recombinant mRNA of any one of claims 11-13, or the expression cassette of claim 14, or the vector of claim 15, or the cell of claim 16, or the recombinant bacterium of claim 17, or the composition of claim 18.
20. A trivalent BVDV mRNA vaccine comprising: (a) the recombinant mRNA according to any one of claims 11 to 13; and (b) a pharmaceutically acceptable carrier.
21. A method for preparing a capped mRNA recombinant expression vector, a non-capped mRNA recombinant expression vector or a self-replicating RNA recombinant expression vector expressing a recombinant trivalent BVDV mRNA, comprising the following steps: Step a: synthesizing the gene fragment of the recombinant nucleic acid according to claim 9 or 10; Step b: constructing a capped mRNA framework vector, constructing a non-capped mRNA framework vector, or constructing a VEE self-replicating vector; The capped mRNA framework vector comprises 5'-UTR, 3'-UTR and polyA sequence and a vector for fixing the capped mRNA framework, and the sequences are shown in SEQ ID NO.3-6 respectively; or, The non-capped mRNA framework vector comprises an IRES sequence, a 3'-UTR and a polyA sequence, and a vector for fixing the non-capped mRNA framework, wherein the sequence of IRES is shown in SEQ ID No.8; or, Constructing a VEE self-replicating vector: obtaining a self-replicating RNA sequence based on the genome of the alpha virus family; the self-replicating RNA sequence contains genes encoding the self-replicating components of the alpha virus and lacks genes for structural proteins that produce infectious alpha virus particles; amplifying the plasmid obtained by constructing the self-replicating RNA sequence as a template, and obtaining the VEE self-replicating vector by synthesis; the sequence of the VEE self-replicating vector is shown in SEQ ID NO.10; Step c: preparing a capped mRNA, a non-capped mRNA or a self-replicating RNA recombinant expression vector; Inserting the gene synthesized in step a into a capped mRNA framework vector to obtain a capped mRNA recombinant expression vector; or, Inserting the gene synthesized in step a into a non-capped mRNA framework vector to obtain a non-capped mRNA recombinant expression vector; or, The gene synthesized in step a is inserted into the designated position of the VEE self-replicating vector to obtain a self-replicating RNA recombinant expression vector.
22. A method for preparing a trivalent BVDV mRNA vaccine, characterized in that: include: (a) providing the recombinant mRNA according to any one of claims 11 to 13; (b) mixing the mRNA with lipid particles and incubating them to form lipid nanoparticles encapsulating the mRNA.
23. A method for preparing a trivalent BVDV capped mRNA framework vector vaccine, a non-capped mRNA framework vector vaccine, or a self-replicating RNA structure vector vaccine, characterized in that: The following steps are included: Step a: linearizing the capped mRNA recombinant expression vector, the non-capped mRNA recombinant expression vector or the self-replicating RNA recombinant expression vector of claim 21 with a restriction endonuclease; Step b: subjecting the linearized capped mRNA recombinant expression vector to an in vitro co-transcription capping reaction, adding a 7-methylated guanylate cap structure to the 5' end of the transcribed mRNA, and degrading the template DNA; or, The linearized non-capped mRNA recombinant expression vector is subjected to an in vitro non-capped transcription reaction, and the template DNA is Degradation; or, The linearized self-replicating RNA recombinant expression vector is subjected to an in vitro co-transcription capping reaction, a 7-methylated guanylate cap structure is added to the 5' end of the transcribed RNA, and the template DNA is degraded; Step c: The capped, non-capped, and self-replicating mRNAs prepared in step b are mixed with lipids respectively, and the mRNA is encapsulated into LNP to obtain an mRNA-LNP complex, and a formulation solution is obtained by concentration and liquid replacement, thereby obtaining the vaccine.
24. Use of the BVDV antigen fragment of claim 1 or 2, or the BVDV antigen fusion fragment of claim 3 or 4, or the trivalent BVDV antigen fusion fragment of any one of claims 5 to 7, or the BVDV antigen fusion protein of claim 8, or the recombinant mRNA of any one of claims 11 to 13 in any of the following: (I) preparing a drug for treating or preventing a disease caused by BVDV infection; or, (II) preparing a drug for treating or preventing bovine viral diarrhea; or (III) preparing a drug for inducing a specific immune response against BVDV in a subject to be administered.
Citation Information
Patent Citations
Combination vaccine comprising an attenuated bovine viral diarrhea virus
CN101360510A
Viral RNA segments as immunomodulatory agents and vaccine components
CN107002079A
Vaccine composition for preventing and treating bovine viral diarrhea and preparation method thereof
CN115364207A
Broad-spectrum mRNA (messenger Ribonucleic Acid) vaccine for resisting bovine viral diarrhea virus and application of mRNA vaccine
CN116284272A
DNA vaccines for farm animals, in particular bovines and porcines
US20020058021A1
